ObjectiveBy adapting to Colombia the model conducted by BresMed and preliminary analysis of transferability, an analysis of cost-effectiveness of treatment of renal denervation vs. best standard treatment in the control of resistant hypertension and cardiovascular events, was performed. MethodsA Markov model was constructed with 32 health states and seven outcomes: stroke, myocardial infarction, coronary artery disease, heart failure, terminal chronic kidney disease, cardiovascular mortality and death. A horizon of lifetime, from the payer perspective and a discount rate of 3% was considered. To calculate the odds of experiencing a cardiovascular event, Framingham risk equations and effectiveness were taken from the trial SYMPLICITY HTN-2. Costs were extracted from the local environment and the mortality rates from the global health observatory of the World Health Organization. The results included the costs of each alternative of treatment, as well as the quality adjusted life years (QALY). Deterministic and probabilistic analyzes were performed. ResultsTreatment of renal denervation generated 12.48 quality adjusted life years gained at a cost of U.S. $ 46,509 vs. 11.68 years of quality adjusted life years gained by the best standard treatment at a cost of U.S. $ 41,199, with an incremental cost per year of quality adjusted life of U.S. $ 6,612. Both univariate sensitivity analysis and probabilistic analysis showed the strength of the results. ConclusionsTreatment of renal denervation, with an incremental cost per quality —adjusted life years gained of $ 6,612, well below 1 GDP of Colombia per capita, showed to be highly cost-effective.